Home/Pipeline/Trikafta/Kaftrio

Trikafta/Kaftrio

Cystic Fibrosis

MarketedActive

Key Facts

Indication

Cystic Fibrosis

Phase

Marketed

Status

Active

Company

Royalty Pharma

About Royalty Pharma

Royalty Pharma is a pioneer and dominant leader in the biopharmaceutical royalty financing sector, having deployed over $25 billion in capital since its 1996 founding. Its mission is to fund the next wave of biopharma innovation by providing non-dilutive capital to partners in exchange for a share of future royalty streams. The company's strategy centers on building a diversified portfolio of royalties across therapeutic areas and development stages, leveraging deep scientific and financial expertise to structure bespoke deals that fuel R&D while generating predictable, long-duration cash flows for investors.

View full company profile

Therapeutic Areas

Oncology Cystic Fibrosis HIV Cardiovascular Autoimmune Diseases Neurology

Other Cystic Fibrosis Drugs

Drug	Company	Phase	Status
CB-280	Calithera Biosciences	Preclinical/Phase 1	Discontinued
Ensifentrine	Verona Pharma	Phase 2	Under MSD
ALTA Drug Series	Alteron Therapeutics	Preclinical	Research
Cystic fibrosis (CRISPR)	GeneToBe	Discovery	Active
Cystic fibrosis (undisclosed)	GeneToBe	Early Discovery	Active
SM001 (alidornase/Tigerase)	SarcoMed USA	Research	Active
Targeted Lung Delivery	Nanite	Pre-clinical	Active
CFTR 100+ Panel	Agena Bioscience	Commercial	Active
RIG-301 CFTR	RIGImmune	Pre-clinical	Active
CBN-101	Carbon Biosciences	Preclinical	Active
RESP® Biosensor Evaluation (with Rutgers Health)	Strados Labs	Research Study	Active
KIT2014	Kither Biotech	Phase 2	Active